Biomerics Launches Online Store for Medical Balloons

Biomerics, LLC, a mid-market medical device contract manufacturer specializing in interventional and radiology markets, launched an online store to sell medical balloons.

Biomerics notes this new e-Commerce platform will sell a range of off-the-shelf Nylon, PET, and LDPE medical balloons. The fast-turn store enables engineers to develop and prototype next-generation catheters quickly.

Chris Richardson, Director of Business Development at Biomerics FMI, expressed, “We have been manufacturing first-in-class balloons for over 25 years. Biomerics currently manufactures over 20,000 balloons per week that are sold as components or further processed into finished medical devices. Launching an online store was the next logical next step for us to add value and convenience to customers. The balloons offered online are standard products and can ship the next day. If you don’t find what you’re looking for, tooling and materials can be modified quickly to develop custom medical balloons.”

The new site, is a sub-site of the Biomerics website. It can take online orders with a credit card and is designed to serve engineers and supply chain managers better. The store is launching with 35 standard balloons to start, but it expected to grow to over 100 sizes quickly. Additional medical balloons and other engineered components such as extrusions will be added over time.

“Offering a fast turn online store is something that customers have requested,” stated Travis Sessions, CEO of Biomerics. “We are excited to develop an online store where we can quickly provide standard engineered components to engineers and accelerate the medical device development process. We look forward to expanding the site over time to include the full range of Biomerics engineer components. I am confident that it will be received well by the MedTech community.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”